CD19 and B-cell non-Hodgkin lymphoma: When used in combination with a chemotherapy regimen that mimicked pediatric induction protocols, SAR3419 was effective at prolonging the duration of remission.117 SAR3419 was then evaluated in a Phase 1 clinical trial with CD19+ B-cell lymphoma.